Study M950
Study name | Kreuzer K 2022 |
Title | The PROVIT study-effects of multispecies probiotic add-on treatment on metabolomics in major depressive disorder-a randomized, placebo-controlled trial |
Overall design | The aim of this study was to investigate the molecular effects of multispecies probiotics on the metabolomic profile of serum and stool in study participants suffering from major depressive disorder (MDD). Inpatients with MDD received treatment as usual and a multispecies-probiotic/vitamin B7 (probiotic group, n = 28) or a placebo/vitamin B7 drink as an add-on therapy (placebo group, n = 29) for 28 days. Then individuals from the intervention group and individuals from the placebo group provided complete stool and serum samples for metabolomics analysis. |
Study Type | Type2; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-IV and ICD-10 diagnosed MDD |
Sample size | 57 |
Tissue | Peripheral; Faece; Faece; Peripheral; Blood; Serum; |
Platform | NMR; NMR: AVANCE Neo Bruker Ultrashield 600 MHz spectrometer; |
PMID | |
DOI | |
Citation | Kreuzer K, Reiter A, Birkl-Toglhofer AM, et al. The PROVIT study-effects of multispecies probiotic add-on treatment on metabolomics in major depressive disorder-a randomized, placebo-controlled trial. Metabolites. 2022 Aug 21;12(8):770. |
Metabolite |
